Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ruxolitinib

- PMLiVE

Fishawack Health welcomes expert-led dermatology initiative FIDE to its group

Fishawack Health welcomes FIDE, an independent organization providing its clients with insight from clinical key opinion leaders in inflammatory dermatology

Avalere Health

- PMLiVE

FDA fast-tracks review of Incyte’s Jakafi for chronic GVHD

Submission is based on results from the pivotal REACH3 study

- PMLiVE

Incyte launches award programme recognising innovation in GVHD community

Programme aims to support people with graft-versus-host disease

- PMLiVE

Incyte’s JAK inhibitor cream clears second eczema trial

Set for regulatory filings later this year

- PMLiVE

Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys

Will pay $750m upfront for co-commercialisation rights

- PMLiVE

Incyte claims FDA priority review for bile duct cancer drug

Significant need for new therapies in hard-to-treat cancer type

Bristol-Myers Squibb (BMS) building

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

Suspends enrolment in BMS-986205 trials for NSCLC and head and neck cancer

- PMLiVE

FDA panel undermines Lilly and Incyte’s baricitinib hopes

Mixed review doesn’t bode well in competitive market

- PMLiVE

Incyte/Merck trial failure bodes ill for IDO class

The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone

Eli Lilly HQ

Lilly planning early re-file for JAK inhibitor baricitinib

The arthritis treatment could reach US market a year earlier than expected

Eli Lilly HQ

FDA turns down Lilly and Incyte JAK inhibitor after delay

Analysts suggest safety issues in high doses

- PMLiVE

Another late-stage setback tarnishes Gilead’s R&D lustre

Myelofibrosis drug candidate fails to best Incyte/Novartis’ Jakafi in phase III trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links